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 Abstract 
Migraine is a common neurovascular brain disorder characterised by recurrent attacks of severe 
headache that may be accompanied by various neurological symptoms. Migraine is thought to result 
from activation of the trigeminovascular system followed by vasodilation of pain-producing 
intracranial blood vessels and activation of second-order sensory neurons in the trigeminal nucleus 
caudalis. Calcitonin gene-related peptide (CGRP) is a mediator of neurogenic inflammation and the 
most powerful vasodilating neuropeptide, and has been implicated in migraine pathophysiology. 
Consequently, genes involved in CGRP synthesis or CGRP receptor genes may play a role in migraine 
and/or increase susceptibility. This study investigates whether variants in the gene that encodes 
CGRP, calcitonin-related polypeptide alpha (CALCA) or in the gene that encodes a component of its 
receptor, receptor activity modifying protein 1 (RAMP1), are associated with migraine pathogenesis 
and susceptibility. The single nucleotide polymorphisms (SNPs) rs3781719 and rs145837941 in the 
CALCA gene, and rs3754701 and rs7590387 at the RAMP1 locus, were analysed in an Australian 
Caucasian population of migraineurs and matched controls. Although we find no significant 
association of any of the SNPs tested with migraine overall, we detected a nominally significant 
association (p=0.031) of the RAMP1 rs3754701 variant in male migraine subjects, although this is 
non-significant after Bonferroni correction for multiple testing. 
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 1. Introduction 
 
Migraine is a common episodic neurological disorder characterized by severe head pain, usually 
accompanied by nausea, vomiting, neurological disturbance, photophobia and phonophobia. 
Migraine affects approximately 6% of men and 17% of women and has significant personal, social 
and economic burdens (Lipton et al., 2007). Two main types of migraine have been classified by the 
International Headache Society (2004), distinguished by the presence of an aura preceding headache 
in the early stages of the attack: migraine with aura (MA) or without aura (MO) (Society, 2004). The 
pathophysiology of migraine is only partially understood, but is believed to be caused by activation 
of the trigeminovascular system which results in vasodilation of pain-producing intracranial blood 
vessels and activation of second-order sensory neurons in the trigeminal nucleus caudalis with 
subsequent perception of pain (Olesen, 2006). Cortical spreading depression (CSD), a slowly 
propagating wave of neuronal and glial depolarisation, is thought to underlie the aura and can 
activate trigeminal nociceptors (Bolay et al., 2002; Zhang et al., 2010). 
 
Family and twin studies have shown that both the rare and common forms of migraine have a 
significant genetic basis. Some insights into the genetics of migraine have come from the 
investigation of the rare severe monogenic migraine subtype Familial Hemiplegic Migraine (FHM) in 
which the genes causal for this type of MA (CACNA1A, ATPA2 and SCNA1) encode proteins involved 
in ion or neurotransmitter transport in the brain (reviewed in (de Vries et al., 2009)). Other loci 
associated with migraine have been found via family (KCNK18, (Lafreniere et al., 2010), genome-
wide association (MTDH, (Anttila et al., 2010) and linkage studies (reviewed in (Maher and Griffiths, 
2011)). Another approach to identifying genes implicated in migraine has been by investigation of 
candidate genes involved in the key biological pathways implicated in migraine pathology. For 
example, SNPs in genes which play a role in neurotransmitter levels in the brain including DBH 
(Fernandez et al., 2006), SLC6A3 (Todt et al., 2009) and various serotonin-related genes (Corominas 
et al., 2010) have shown  positive associations with migraine, as have other neurological, hormonal 
and vascular candidate genes, in certain migraine populations (de Vries et al., 2009; Maher and 
Griffiths, 2011).  Paragraphs 2 and 3 condensed and some text left out. 
 
Calcitonin gene-related polypeptide-alpha (-CGRP) encoded by the CALCA gene is a 37 amino acid 
neuropeptide that is a potent vasodilator and is one of the mediators of neurogenic inflammation. 
CGRP-related genes are good candidates to screen for an association with migraine susceptibility as 
several lines of evidence suggest that -CGRP is a key player in migraine pathology. Plasma levels of 
CGRP have been found to be elevated during spontaneous and nitroglycerin-induced migraine 
attacks (Goadsby et al., 1990; Juhasz et al., 2003) and reduced by the anti-migraine agent 
sumatriptan, co-incident with pain relief (Goadsby and Edvinsson, 1993). Some recent well-
controlled studies have questioned this, but the controversy may be explained by reports of higher 
plasma CGRP levels outside of a migraine attack in migraineurs compared with control individuals. 
Importantly, individuals with migraine (Lassen et al., 2002), but not healthy controls develop a 
migraine-like headache in response to intravenous administration of CGRP, suggesting that 
migraineurs are especially sensitive to CGRP. Finally CGRP receptor antagonists are effective at 
alleviating the pain and associated symptoms of a migraine attack (Edvinsson and Ho, 2010). 
Together these findings suggest that the direct effect of CGRP on its receptor is crucial in the 
initiation and perpetuation of a migraine attack. Paragraphs 4 and 5 condensed and some text left 
out. 
 
-CGRP is expressed in trigeminal ganglia neurons (TGNs) and is the main mediator of dilation in 
human cerebral arteries. It acts via CGRP receptors which are located at several sites, including the 
cerebrovasculature, the trigeminocervical complex within the brainstem and the trigeminal ganglion 
(Oliver et al., 2002; Storer et al., 2004; Petersen et al., 2005; Zhang et al., 2007). The CGRP receptor 
is a G protein coupled receptor that is a multimer of calcitonin receptor-like receptor (CLR), a 
receptor component protein (RCP) which is involved in coupling the receptor to downstream 
signalling pathways, and receptor activity-modifying protein 1 (RAMP1). RAMP1 is a small single-
transmembrane protein that is required for CGRP binding by CLR and, in addition to ligand-
specificity, influences CLR glycosylation and cell surface trafficking (McLatchie et al., 1998; Steiner et 
al., 2002). RAMP1 overexpressing mice display photophobia and mechanical allodynia, two of the 
symptoms of migraine, suggesting that regulation of this single gene could potentially contribute to 
migraine susceptibility (Russo et al., 2009). In the present study we have selected two SNPs in the 
CALCA gene, as well as two SNPs around the RAMP1 gene, to investigate whether they contribute to 
the risk of migraine in an Australian Caucasian population. Paragraphs 6 and 7 condensed and some 
text left out. 
 
2. Materials and Methods 
 
2.1 Subjects 
A cohort of 284 migraineurs and 284 controls matched for sex, age (+/-5 years) and ethnicity, 
recruited from in and around South Eastern Australia was used for this study (Colson et al., 2004). All 
individuals provided informed consent and were adult Caucasians of European decent living in 
Australia, having ancestors who emigrated within the last 160 years from various locations within 
the British Isles and other parts of Europe. Migraineurs were diagnosed by a clinical neurologist as 
having either MA or MO based strictly on the widely accepted criteria specified by the IHS (Society, 
2004). The study was approved by the Griffith University Ethics Committee for Experimentation on 
Human Subjects. A whole blood sample was collected from each participant and genomic DNA was 
extracted from white blood cells using a standard salting out method (Miller et al., 1988). Samples 
used for the genotyping study were all from unrelated individuals and the control group consisted of 
individuals with no family history of migraine. 
 
2.2 Genotyping 
Genotype for each SNP was determined by restriction-fragment length polymorphism (RFLP) analysis 
of restriction enzyme-digested PCR products on agarose gels. A 20-l PCR reaction mix contained 1x 
PCR buffer, 1.75 mM MgCl2, 0.2 mM dNTPs, 0.15 M of each primer, 20-40 ng of genomic DNA and 
1.5U of GoTaq® (Promega). Thermocycler conditions were an initial denaturation at 95°C for 10 min, 
followed by 35 cycles of 95°C for 45 s, 60°C for 45s, 72°C for 45 s and a final extension step of 72°C 
for 7 min. Specific primers were used to amplify each region containing the SNPs and restriction 
enzymes (NEB) chosen that would differentiate the two alleles after separation on 3% agarose gels. 
Two SNPs from the CALCA gene and two SNPs from the RAMP1 gene were analysed as follows: 
rs3781719 is the first SNP of a closely linked double base exchange at position -624 (T/C) of the 
CALCA gene promoter. The primers 5’-GCTGTTTCTCACAATATTCC and 5’-CAATTCCTGGTTGTGTGATC 
generate a 109-bp PCR product which with BsmAI is digested into 86- and 23-bp fragments in the 
case of the ‘C’ allele mutation. 
rs145837941 is a SNP located in the coding sequence of the CALCA gene common to both calcitonin 
and CGRP-. A 4218T>C base-exchange results in a non-synonymous amino acid change (Leu66Pro). 
The primers 5’-AGCCTGCACTGAGTTTGCTTCCC and 5’- ATCCACCTTCCTGTGTATGCTGCG generate a 
236-bp PCR product which with AluI is digested into 140- and 96-bp fragments in the case of the wild 
type ‘T’ allele. 
rs3754701 is a SNP in the RAMP1 gene promoter at position -1166 (T/A). The primers 5’-
TGGCCTCTCGGCATTACTG and 5’-TGCACAGGTGGTAGGCATG generate a 373-bp PCR product which 
with AclI is digested into 215-bp and 158-bp fragments in the case of the ‘A’ allele mutation. 
rs7590387 is a SNP (G/C) located 1.4 kb downstream of the RAMP1 gene. The primers 5’-
AGAGCCTGTCGTTGTGCCCA and 5’-CTCCCGTCTCCTCGCCCTCA generate a 284-bp product which with 
XcmI is digested into 194- and 90-bp fragments in the case of the ‘C’ allele mutation. 
 
2.3 Statistical analysis 
Hardy-Weinberg equilibrium was verified for observed genotype frequencies for each SNP to detect 
deviation from the normal genotype distribution in the population. Chi-square (χ2) analysis was 
performed for each SNP to test for significant differences in genotype and allele frequencies in 
migraineurs MA, MO and combined migraine groups versus control results to detect any association 
with migraine. The results were also broken down into female and male sub-populations. The 
Statistical Package for Social Sciences (SPSS version 19.0) was used for all computations. Power 
analysis indicated that if the polymorphism were to confer a two-fold increase in risk of migraine, 
the case and control groups used in this study were of sufficient size to have ~80% power to detect 
an allelic association at the 0.05 level.  
3. Results 
 
In a study to investigate the role of the CALCA gene in psychiatric or neurological disease based on 
the neuromodulatory role of -CGRP in dopaminergic transmission, Buervenich et al., (2001) 
identified four novel polymorphisms at the CALCA locus (Buervenich et al., 2001). While no positive 
association was found for any of these polymorphisms with Parkinson’s disease or schizophrenia, 
because of the important role of CGRP in migraine pathogenesis, we wished to investigate them with 
respect to migraine susceptibility. We previously found no association with migraine for a 16-bp 
deletion polymorphism in intron 1 of CALCA (Menon et al., 2011). However, in the present study we 
investigated a polymorphism in the promoter of CALCA (rs3781719) which may influence 
transcription of -CGRP, and the 4218T>C base-exchange (rs145837941) which results in a non-
synonymous change (Leu66Pro) of a highly conserved amino acid which likely to disrupt structure of 
the CALCA propeptide. The RAMP1 SNPs that we tested in this study were previously identified as 
part of a susceptibility haplotype for cerebral infarction (Nakazato et al., 2010). We were interested 
in the RAMP1 promoter SNP rs3754701, as it sits within a DNaseI hypersensitive site in a number of 
cell lines according to the ENCODE project and is also under the binding regions for a number of 
transcription factors including CTCF, c-myc, Znf143, GABP, CHD2 and Rad2 according to ENCODE 
ChIP-seq data. We also investigated rs7590387 which is downstream of RAMP1, but in a region that 
we found to show some association with migraine (unpublished results) in a GWAS study of the 
Norfolk Island population (Cox et al., 2012). New text to address reviewers comments about SNP 
selection. 
 
The genotypes for the two CALCA gene SNPs and the two RAMP1 gene SNPs were determined using 
RFLP analysis. Chi-square (χ2) analysis demonstrated that genotypes for all four SNPs were in Hardy-
Weinberg equilibrium in both control and migraine groups. 
 
CALCA rs3781719 
A total of 434 individuals were successfully genotyped for the CALCA promoter SNP, rs3781719, 
including 203 controls and 228 migraine cases, of which 147 were diagnosed with MA and 81 with 
MO. It should be noted that although MA typically accounts for only a third of migraineurs, our 
migraine population has a higher proportion of MA cases compared to MO, probably as the more 
severe MA-sufferers are more likely to identify as migrainuers and/or volunteer. χ2-analysis was 
performed to compare the genotype and allele frequencies in the migraine population to controls, 
as well as the subgroups of migraineurs with aura to the controls and migraineurs without aura to 
controls (Table 1). No significant difference in genotype frequencies were found between cases and 
controls (p=0.260), MA and controls (p=0.563), nor MO and controls (p=0.133). There was also no 
significant difference in allele frequencies between cases and controls (p=0.333), MA and controls 
(p=0.370), nor MO and controls (p=0.593). The genotype and allele frequencies were also compared 
between migraineurs and controls sub-grouped into each of the genders (Table 1). No significant 
differences were seen between genotype or allele frequencies for female migraineurs compared to 
controls (p=0.270 and p=0.993, respectively). Similarly for the male sub-population, there was no 
significant difference between migraineurs and controls for either genotypes (p=0.163) or alleles 
(p=0.055), although the latter is close to significance. Table 1a and 1b now condensed into a single 
table. 
 
Table 1. Genotype and allele frequency distributions for the CALCA rs3781719 SNP in migraine and 
control groups and subgrouped by gender. 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
TT (%) TC (%) CC (%) T (%) C (%) 
          
Migraine 228 109 
(47.8) 
102 
(44.7) 
17 
(7.5) 
0.260 456 320 
(70.2) 
136 
(29.8) 
0.333 
MA 147 72 
(49.0) 
62 
(42.2) 
13 
(8.8) 
0.563 294 206 
(70.0) 
88 
(30.0) 
0.370 
MO 81 37 
(45.7) 
40 
(49.4) 
4 
(4.9) 
0.133 162  114 
(70.4) 
48 
(29.6) 
0.593 
Control 203 111 
(54.7) 
75 
(36.9) 
17 
(8.4) 
- 406 297 
(73.2) 
109 
(26.8) 
- 
 
          
Females          
Migraine 172 82 
(47.7) 
79 
(45.9) 
11  
(6.4) 
0.270 344 243 
(70.6) 
101 
(29.4) 
0.993 
Control 148 76 
(51.4) 
57 
(38.5) 
15 
(10.1) 
- 296 209 
(70.6) 
87 
(29.4) 
- 
          
Males          
Migraine 56 27 
(48.2) 
23 
(41.1) 
6  
(10.7) 
0.163 112 77 
(68.8) 
35 
(31.2) 
0.055 
Control 55 35 
(63.6) 
18 
(32.7) 
2  
(3.6) 
- 110 88 
(80.0) 
22 
(20.0) 
- 
MA- Migraine with aura, MO- Migraine without aura 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
N is total number of genotypes or alleles. 
 
CALCA rs145837941 
rs145837941 is a SNP located in the coding sequence of the CALCA gene common to both calcitonin 
and -CGRP. A 4218T>C base-exchange results in a non-synonymous amino acid change (Leu66Pro). 
A total of 462 individuals were genotyped for rs145837941, which included 236 migraine cases and 
226 controls (Table 2).  Because the CC genotype was very rare, the TC and CC genotypes were 
pooled together for analysis versus the wild type TT genotype for chi-square analysis between 
migraineurs and controls, however no significant difference was observed (p=0.913). Similarly there 
was no significant difference for alleles between cases and controls (p=0.926). No further analysis in 
subgroups was done because of the rarity of the C-allele. Furthermore, neither marker is in LD with 
16 bp deletion polymorphism that we previously genotyped in this population (r2=0.088, p=0.205 for 
rs3781719 and r2=0.042, p=0.541 for rs145837941). The HapMap data release 27 shows poor variant 
coverage in this region. 
 
Table 2. Genotype and allele frequency distributions for the CALCA rs145837941 SNP in migraine 
and control groups 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
TT (%) TC (%) CC (%) T (%) C (%) 
          
Migraine 236 224 
(94.9) 
11  
(4.7) 
1  
(0.4) 
0.913 472 459 
(97.2) 
13  
(2.8) 
0.926 
Control 226 214 
(94.7) 
12  
(5.3) 
0  
(0) 
- 452 440 
(97.3) 
12  
(2.7) 
- 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
Because of the rarity of the C-allele, the P-value for genotypes was calculated for the TT genotype 
versus TC and CC genotypes pooled together. 
 
RAMP1 rs3754701 
rs3754701 is a SNP in the RAMP1 gene promoter at position -1166 (T/A). A total of 485 individuals 
were successfully genotyped for rs3754701 comprised of 243 migraine cases (broken down into 145 
MA and 98 MO patients), and 242 controls (Table 3). No significant difference in genotypic 
frequencies were found between cases and controls (p=0.360), MA and controls (p=0.276), nor MO 
and controls (p=0.260). No significant difference was found for genotypes frequencies between 
cases and controls (p=0.370), MA and controls (p=0.276), nor MO and controls (p=0.260) and for 
allelic frequencies between cases and controls (p=0.376), MA and controls (p=0.912), nor MO and 
controls (p=0.129). The genotype and allele frequencies were also compared between migraineurs 
and controls of the two genders (Table 3). No significant differences were seen between genotypic 
or allelic frequencies for female migraineurs compared to controls (p=0.560 and p=0.819, 
respectively). For the male sub-population, although close, the difference between migraineurs and 
controls was not significant for genotypes (p=0.068), but a significant difference in the allelic 
frequency was observed between migraineurs and controls (p=0.031). However, with Bonferroni 
correction of the p-value to an alpha of 0.0056 (considering the entire group and sub-group 
analyses) the result is non-significant. 
 
Table 3a and 3b now condensed into a single table. 
Table 3. Genotype and allele frequency distributions for the RAMP1 rs3754701 SNP in migraine 
and control groups and subgrouped by gender. 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
TT (%) TA (%) AA (%) T (%) A (%) 
          
Migraine 243 91 
(37.4) 
120 
(49.4) 
32 
(13.2) 
0.360 494 302 
(61.1) 
184 
(38.9) 
0.376 
MA 145 61 
(42.1) 
65 
(44.8) 
19 
(13.1) 
0.276 290 187 
(64.5) 
103 
(35.5) 
0.912 
MO 98 30 
(30.6) 
55 
(56.1) 
13 
(13.3) 
0.260 196 115 
(58.7) 
81 
(41.3) 
0.129 
Control 242 94 
(38.8) 
126 
(52.1) 
22 
(9.1) 
- 484 314 
(64.9) 
170 
(35.1) 
 
          
Females          
Migraine 183 71 
(38.8) 
89 
(48.6) 
23 
(12.6) 
0.560 366 231 
(63.1) 
135 
(36.9) 
0.819 
Control 179 63 
(35.2) 
97 
(54.2) 
19 
(10.6) 
- 358 223 
(62.3) 
135 
(37.7) 
- 
          
Males          
Migraine 60 20 
(33.3) 
31 
(51.7) 
9 
(15.0) 
0.068 120 71 
(59.2) 
49 
(40.8) 
0.031 
Control 63 31 
(49.2) 
29 
(46.0) 
3 
(4.8) 
- 126 91 
(72.2) 
35 
(27.8) 
- 
MA- Migraine with aura, MO- Migraine without aura 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
N is total number of genotypes or alleles. 
 
RAMP1 rs7590387 
rs7590387 is a SNP (C/G) located 1.4 kb downstream of the RAMP1 gene. A total of 456 individuals 
were successfully genotyped for rs7590387, consisting of 226 migraine cases (138 MA and 88 MO 
patients), and 230 controls. A chi-square analysis (χ2) was performed to compare the allele and 
genotype frequencies of the migraine population to the controls (Table 4). No significant differences 
in genotypic frequencies were found between migraineurs and controls (p=0.341), MA and controls 
(p=0.566), nor MO and controls (p=0.299) and for allelic frequencies between migraineurs and 
controls (p=0.461), MA and controls (p=0.864), nor MO and controls (p=0.236). When migraineurs 
and controls were split into the two genders for analysis (Table 4), there were no significant 
differences between genotypic or allelic frequencies for female migraineurs compared to controls 
(p=0.865 and p=0.769, respectively), or for male migraineurs compared to controls (p=0.188 and 
p=0.366, respectively). According to CEPH Caucasian HapMap LD data rs3754701 and rs7590387 are 
not correlated (r2=0.005) and we also find in our population that these two SNPs are not in LD 
(r2=0.094, p=0.126). 
 
 Table 4a and 4b now condensed into a single table. 
Table 4. Genotype and allele frequency distributions for the RAMP1 rs7590387 SNP in migraine 
and control groups and subgrouped by gender. 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
GG (%) GC (%) CC (%) G (%) C (%) 
          
Migraine 226 58 
(25.7) 
123 
(54.4) 
45 
(19.9) 
0.341 452 239 
(52.1) 
213 
(47.1) 
0.461 
MA 138 33 
(23.9) 
75 
(54.3) 
30 
(21.7) 
0.566 276 141 
(51.1) 
135 
(48.9) 
0.864 
MO 88 25 
(28.4) 
48 
(54.5) 
15 
(17.0) 
0.299 176 98 
(55.7) 
78 
(44.3) 
0.236 
Control 230 60 
(26.1) 
112 
(48.7) 
58 
(25.2) 
- 460 232 
(50.4) 
228 
(49.6) 
- 
          
Females          
Migraine 171 44 
(25.7) 
93 
(54.4) 
34 
(19.9) 
0.865 342 181 
(52.9) 
161 
(47.1) 
0.769 
Control 172 43 
(25.7) 
87 
(52.1) 
37 
(22.2) 
- 334 173 
(51.8) 
161 
(48.2) 
- 
          
Males          
Migraine 55 14 
(25.5) 
30 
(54.5) 
11 
(20.0) 
0.188 110 58 
(52.7) 
52 
(47.3) 
0.366 
Control 63 17 
(27.0) 
25 
(39.7) 
21 
(33.3) 
- 126 59 
(46.8) 
67 
(53.2) 
- 
MA- Migraine with aura, MO- Migraine without aura 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
N is total number of genotypes or alleles. 
 
 
4. Discussion 
The identification of susceptibility genes for complex traits such as migraine can be challenging, in 
particular due to the contribution of multiple, and potentially interacting, loci as well as the 
confounding influence of environmental factors. However, unravelling the genetic basis of migraine 
should improve our understanding of the pathogenesis of the disease and may suggest pathways to 
which therapies can be targeted. Both the CALCA and RAMP1 genes are good candidates to 
investigate whether polymorphisms at these loci play a role in migraine pathogenesis and/or 
susceptibility due to the well-documented relationship of CGRP with migraine. However, neither the 
16-bp deletion in intron 1 of the CALCA gene that we tested previously (Menon et al., 2011), nor the 
two other CALCA SNPs and two RAMP1 SNPs that we tested in this study, show a significant 
difference between the migraine and control groups, the MA and control groups, or the MO and 
control groups in this Australian population. In line with this, no positive association of the four SNPs 
in this study was found when the analysis was performed with female samples. An increase in 
frequency of the minor C-allele of the rs3781719 SNP in the promoter of the CALCA gene in male 
migraineurs was close to significance (p=0.055) and for one of the SNPs, rs3754701 which is in the 
promoter of the RAMP1 gene, we observed a nominally significant increase in the frequency of the 
minor A-allele in male migraineurs (p= 0.031). However, the result is not significant with Bonferroni 
correction for multiple testing which gives a corrected p-value threshold of 0.0056. Because fewer 
males are affected by migraine than females, the number of male subjects in our population is low, 
so the association may be a false positive. However, sex-specific differences in mRNA levels of CGRP 
and CGRP receptor components including RAMP1 have been found before and after induction of 
migraine-like symptoms in a rat preclinical migraine model (Stucky et al., 2011); furthermore, sex- 
specific differences are also apparent in the migraine-relevant behaviour of light aversion in mice 
overexpressing transgenic RAMP1 (Recober et al., 2009), suggesting that the result is potentially 
interesting. Future studies could look at these markers using a larger cohort, in particular of male 
subjects, in order to follow up any potential associations. While female sex hormones have a role in 
migraine and may help explain the preponderance of female migraine sufferers (Shyti et al., 2011), 
polymorphisms in some genes have been more strongly linked in males to either migraine, such as 
DBH (Fernandez et al., 2006) or particular migraine phenotypes, such as the C667T polymorphism in 
MTHFR (Liu et al., 2010). 
The products of the CALCA gene including calcitonin, -CGRP, their propeptides and other cleavage 
products exert many functions in the body. Mutations in a calcitonin receptor have been associated 
with altered bone density and decreased fracture risk in postmenopausal women (Masi et al., 1998; 
Taboulet et al., 1998). CGRP is vasodilator in peripheral organs as well as the brain and 
polymorphisms in CALCA gene have been linked to essential hypertension in Japanese and Chinese 
populations (Morita et al., 2007; Luo et al., 2008). A previous study had found no difference between 
migraine cases and controls for another CALCA gene promoter SNP (rs1553005) in a European 
population (Lemos et al., 2010). According to CEPH Caucasian HapMap LD data rs1553005 is in 
complete LD with rs3781719, however, we decided to test rs3781719 in our migraine population for 
a number of reasons. Firstly, we have a greater proportion of MA compared to MO cases, which 
would give us greater power to detect any association that is specific for this subgroup of migraine, 
and furthermore, our population is primarily made up of Northern European, i.e. British 
descendants, compared to the Southern European Portuguese cohort of that study and there is 
some genetic disparity between European populations. However, we found no significant 
association of either of the CALCA SNPs in this study with overall migraine or either MA or MO. The 
Lemos et al. (2010) study also investigated SNPs at the BDNF locus and, while no individual 
associations were detected, an increased risk for one of the genotype pairs of this particular CALCA 
SNP (rs1553005) and a BDNF SNP in migraineurs was found, suggesting interaction between these 
genes in migraine susceptibility. BDNF is co-expressed with CGRP in trigeminal ganglion neurons in 
rats and CGRP enhances the release of BDNF (Buldyrev et al., 2006) so future studies of CGRP-
related genes in migraine could focus on interactions between loci. 
Many of the anti-migraine drugs currently available target some action of CGRP action. Triptans act 
in part by inhibiting trigeminal release of CGRP (Bigal et al., 2009), while olcegepant (BIBN-4096BS) 
and telcagepant (MK-0974) are CGRP receptor antagonists (Olesen et al., 2004; Ho et al., 2008; 
Edvinsson and Ho, 2010). Some migraineurs respond better with certain migraine drugs than others 
and some fail to respond at all; studies have investigated SNPs in some factors and genes that may 
be involved (Ishii et al., 2012). Although we failed to detect association with migraine for the CALCA 
and RAMP1 variations that we have looked at in this study, these genes could also potentially play a 
role in drug response to anti-migraine agents. 
In conclusion, we investigated whether the SNPs rs3754701 and rs7590387 in RAMP1 and rs3781719 
and rs145837941 in the CALCA locus are associated with migraine susceptibility. We find no 
significant association of any of the SNPs tested with migraine overall. We did detect a nominally 
significant association of the minor A-allele for RAMP1 rs3754701 in male migraine subjects, but this 
was no longer significant after Bonferroni correction. Although RAMP1, via its interaction with CGRP, 
has been implicated in migraine (Recober et al., 2009), our study is the first to investigate 
polymorphisms in the RAMP1 gene in a migraine population. Future studies using a larger 
population to increase the power to detect significant associations, and greater gene coverage and 
haplotype analysis, would clarify whether polymorphisms in CGRP-related genes play a role in 
migraine. 
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 Abstract 
Migraine is a common neurovascular brain disorder characterised by recurrent attacks of severe 
headache that may be accompanied by various neurological symptoms. Migraine is thought to result 
from activation of the trigeminovascular system followed by vasodilation of pain-producing 
intracranial blood vessels and activation of second-order sensory neurons in the trigeminal nucleus 
caudalis. Calcitonin gene-related peptide (CGRP) is a mediator of neurogenic inflammation and the 
most powerful vasodilating neuropeptide, and has been implicated in migraine pathophysiology. 
Consequently, genes involved in CGRP synthesis or CGRP receptor genes may play a role in migraine 
and/or increase susceptibility. This study investigates whether variants in the gene that encodes 
CGRP, calcitonin-related polypeptide alpha (CALCA) or in the gene that encodes a component of its 
receptor, receptor activity modifying protein 1 (RAMP1), are associated with migraine pathogenesis 
and susceptibility. The single nucleotide polymorphisms (SNPs) rs3781719 and rs145837941 in the 
CALCA gene, and rs3754701 and rs7590387 at the RAMP1 locus, were analysed in an Australian 
Caucasian population of migraineurs and matched controls. Although we find no significant 
association of any of the SNPs tested with migraine overall, we detected a nominally significant 
association (p=0.031) of the RAMP1 rs3754701 variant in male migraine subjects, although this is 
non-significant after Bonferroni correction for multiple testing. 
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 1. Introduction 
 
Migraine is a common episodic neurological disorder characterized by severe head pain, usually 
accompanied by nausea, vomiting, neurological disturbance, photophobia and phonophobia. 
Migraine affects approximately 6% of men and 17% of women and has significant personal, social 
and economic burdens (Lipton et al., 2007). Two main types of migraine have been classified by the 
International Headache Society, IHS (Society, 2004), distinguished by the presence of an aura 
preceding headache in the early stages of the attack: migraine with aura (MA) or without aura (MO) 
(Society, 2004). The pathophysiology of migraine is only partially understood, but is believed to be 
caused by activation of the trigeminovascular system which results in vasodilation of pain-producing 
intracranial blood vessels and activation of second-order sensory neurons in the trigeminal nucleus 
caudalis with subsequent perception of pain (Olesen, 2006). Cortical spreading depression (CSD), a 
slowly propagating wave of neuronal and glial depolarisation, is thought to underlie the aura and can 
activate trigeminal nociceptors (Bolay et al., 2002; Zhang et al., 2010). 
 
Family and twin studies have shown that both the rare and common forms of migraine have a 
significant genetic basis. Some insights into the genetics of migraine have come from the 
investigation of the rare severe monogenic migraine subtype Familial Hemiplegic Migraine (FHM) in 
which the genes causal for this type of MA (CACNA1A, ATPA2 and SCNA1) encode proteins involved 
in ion or neurotransmitter transport in the brain (reviewed in de Vries et al., 2009). Other loci 
associated with migraine have been found via family, e.g. KCNK18 (Lafreniere et al., 2010), genome-
wide association, e.g. MTDH (Anttila et al., 2010), and linkage studies (reviewed in Maher and 
Griffiths, 2011). Another approach to identifying genes implicated in migraine has been by 
investigation of candidate genes involved in the key biological pathways implicated in migraine 
pathology. For example, SNPs in genes which play a role in neurotransmitter levels in the brain 
including DBH (Fernandez et al., 2006), SLC6A3 (Todt et al., 2009) and various serotonin-related 
genes (Corominas et al., 2010) have shown  positive associations with migraine, as have other 
neurological, hormonal and vascular candidate genes, in certain migraine populations (de Vries et 
al., 2009; Maher and Griffiths, 2011).  
 
Calcitonin gene-related polypeptide-alpha (-CGRP) encoded by the CALCA gene is a 37 amino acid 
neuropeptide that is a potent vasodilator and is one of the mediators of neurogenic inflammation. 
CGRP-related genes are good candidates to screen for an association with migraine susceptibility as 
several lines of evidence suggest that -CGRP is a key player in migraine pathology. Plasma levels of 
CGRP have been found to be elevated during spontaneous and nitroglycerin-induced migraine 
attacks (Goadsby et al., 1990; Juhasz et al., 2003) and are reduced by the anti-migraine agent 
sumatriptan, co-incident with pain relief (Goadsby and Edvinsson, 1993). Some recent well-
controlled studies have questioned this, but the controversy may be explained by reports of higher 
plasma CGRP levels outside of a migraine attack in migraineurs compared with control individuals. 
Importantly, individuals with migraine (Lassen et al., 2002), but not healthy controls develop a 
migraine-like headache in response to intravenous administration of CGRP, suggesting that 
migraineurs are especially sensitive to CGRP. Finally CGRP receptor antagonists are effective at 
alleviating the pain and associated symptoms of a migraine attack (Edvinsson and Ho, 2010). 
Together these findings suggest that the direct effect of CGRP on its receptor is crucial in the 
initiation and perpetuation of a migraine attack. 
 
-CGRP is expressed in trigeminal ganglia neurons (TGNs) and is the main mediator of dilation in 
human cerebral arteries. It acts via CGRP receptors which are located at several sites, including the 
cerebrovasculature, the trigeminocervical complex within the brainstem and the trigeminal ganglion 
(Oliver et al., 2002; Storer et al., 2004; Petersen et al., 2005; Zhang et al., 2007). The CGRP receptor 
is a G protein coupled receptor that is a multimer of calcitonin receptor-like receptor (CLR), a 
receptor component protein (RCP) which is involved in coupling the receptor to downstream 
signalling pathways, and receptor activity-modifying protein 1 (RAMP1). RAMP1 is a small single-
transmembrane protein that is required for CGRP binding by CLR and, in addition to ligand-
specificity, influences CLR glycosylation and cell surface trafficking (McLatchie et al., 1998; Steiner et 
al., 2002). RAMP1 overexpressing mice display photophobia and mechanical allodynia, two of the 
symptoms of migraine, suggesting that regulation of this single gene could potentially contribute to 
migraine susceptibility (Russo et al., 2009). In the present study we have selected two SNPs in the 
CALCA gene, as well as two SNPs around the RAMP1 gene, to investigate whether they contribute to 
the risk of migraine in an Australian Caucasian population. 
 
 
2. Materials and Methods 
 
2.1 Subjects 
A cohort of 284 migraineurs and 284 controls matched for sex, age (+/-5 years) and ethnicity, 
recruited from in and around South Eastern Australia was used for this study (Colson et al., 2004). All 
individuals provided informed consent and were adult Caucasians of European decent living in 
Australia, having ancestors who emigrated within the last 160 years from various locations within 
the British Isles and other parts of Europe. Migraineurs were diagnosed by a clinical neurologist as 
having either MA or MO based strictly on the widely accepted criteria specified by the IHS (Society, 
2004). The study was approved by the Griffith University Ethics Committee for Experimentation on 
Human Subjects. A whole blood sample was collected from each participant and genomic DNA was 
extracted from white blood cells using a standard salting out method (Miller et al., 1988). Samples 
used for the genotyping study were all from unrelated individuals and the control group consisted of 
individuals with no family history of migraine. 
 
2.2 Genotyping 
Genotype for each SNP was determined by restriction-fragment length polymorphism (RFLP) analysis 
of restriction enzyme-digested PCR products on agarose gels. A 20-l PCR reaction mix contained 1x 
PCR buffer, 1.75 mM MgCl2, 0.2 mM dNTPs, 0.15 M of each primer, 20-40 ng of genomic DNA and 
1.5U of GoTaq® (Promega). Thermocycler conditions were an initial denaturation at 95°C for 10 min, 
followed by 35 cycles of 95°C for 45 s, 60°C for 45s, 72°C for 45 s and a final extension step of 72°C 
for 7 min. Specific primers were used to amplify each region containing the SNPs and restriction 
enzymes (NEB) chosen that would differentiate the two alleles after separation on 3% agarose gels. 
Two SNPs from the CALCA gene and two SNPs from the RAMP1 gene were analysed as follows: 
rs3781719 is the first SNP of a closely linked double base exchange at position -624 (T/C) of the 
CALCA gene promoter. The primers 5’-GCTGTTTCTCACAATATTCC and 5’-CAATTCCTGGTTGTGTGATC 
generate a 109-bp PCR product which with BsmAI is digested into 86- and 23-bp fragments in the 
case of the ‘C’ allele mutation. 
rs145837941 is a SNP located in the coding sequence of the CALCA gene common to both calcitonin 
and CGRP-. A 4218T>C base-exchange results in a non-synonymous amino acid change (Leu66Pro). 
The primers 5’-AGCCTGCACTGAGTTTGCTTCCC and 5’- ATCCACCTTCCTGTGTATGCTGCG generate a 
236-bp PCR product which with AluI is digested into 140- and 96-bp fragments in the case of the wild 
type ‘T’ allele. 
rs3754701 is a SNP in the RAMP1 gene promoter at position -1166 (T/A). The primers 5’-
TGGCCTCTCGGCATTACTG and 5’-TGCACAGGTGGTAGGCATG generate a 373-bp PCR product which 
with AclI is digested into 215-bp and 158-bp fragments in the case of the ‘A’ allele mutation. 
rs7590387 is a SNP (G/C) located 1.4 kb downstream of the RAMP1 gene. The primers 5’-
AGAGCCTGTCGTTGTGCCCA and 5’-CTCCCGTCTCCTCGCCCTCA generate a 284-bp product which with 
XcmI is digested into 194- and 90-bp fragments in the case of the ‘C’ allele mutation. 
 
2.3 Statistical analysis 
Hardy-Weinberg equilibrium was verified for observed genotype frequencies for each SNP to detect 
deviation from the normal genotype distribution in the population. Chi-square (χ2) analysis was 
performed for each SNP to test for significant differences in genotype and allele frequencies in 
migraineurs MA, MO and combined migraine groups versus control results to detect any association 
with migraine. The results were also broken down into female and male sub-populations. The 
Statistical Package for Social Sciences (SPSS version 19.0) was used for all computations. Power 
analysis indicated that if the polymorphism were to confer a two-fold increase in risk of migraine, 
the case and control groups used in this study were of sufficient size to have ~80% power to detect 
an allelic association at the 0.05 level.  
3. Results 
 
In a study to investigate the role of the CALCA gene in psychiatric or neurological disease based on 
the neuromodulatory role of -CGRP in dopaminergic transmission, Buervenich et al., (2001) 
identified four novel polymorphisms at the CALCA locus (Buervenich et al., 2001). While no positive 
association was found for any of these polymorphisms with Parkinson’s disease or schizophrenia, 
because of the important role of CGRP in migraine pathogenesis, we wished to investigate them with 
respect to migraine susceptibility. We previously found no association with migraine for a 16-bp 
deletion polymorphism in intron 1 of CALCA (Menon et al., 2011). However, in the present study we 
investigated a SNP at position -624 (T/C) of the CALCA gene promoter (rs3781719), which may 
influence transcription of -CGRP, and the 4218T>C base-exchange (rs145837941) in the coding 
sequence of the CALCA gene common to both calcitonin and -CGRP, which results in a non-
synonymous change (Leu66Pro) of a highly conserved amino acid and is likely to disrupt structure of 
the CALCA propeptide. The RAMP1 SNPs that we tested in this study were previously identified as 
part of a susceptibility haplotype for cerebral infarction (Nakazato et al., 2010). We were interested 
in the RAMP1 promoter SNP rs3754701 at position -1166 (T/A), as it sits within a DNaseI 
hypersensitive site in a number of cell lines according to the ENCODE project and is also under the 
binding regions for a number of transcription factors including CTCF, c-myc, Znf143, GABP, CHD2 and 
Rad2 according to ENCODE ChIP-seq data. We also investigated rs7590387, a C/G SNP which is 1.4 kb 
downstream of RAMP1, but in a region that we found to show some association with migraine 
(unpublished results) in a GWAS study of the Norfolk Island population (Cox et al., 2012). 
 
The genotypes for the two CALCA gene SNPs and the two RAMP1 gene SNPs were determined using 
RFLP analysis. Chi-square (χ2) analysis demonstrated that genotypes for all four SNPs were in Hardy-
Weinberg equilibrium in both control and migraine groups. 
 
CALCA rs3781719 
A total of 434 individuals were successfully genotyped for the CALCA promoter SNP, rs3781719, 
including 203 controls and 228 migraine cases, of which 147 were diagnosed with MA and 81 with 
MO. It should be noted that although MA typically accounts for only a third of migraineurs, our 
migraine population has a higher proportion of MA cases compared to MO, probably as the more 
severe MA-sufferers are more likely to identify as migrainuers and/or volunteer. χ2-analysis was 
performed to compare the genotype and allele frequencies in the migraine population to controls, 
as well as the subgroups of migraineurs with aura to the controls and migraineurs without aura to 
controls (Table 1). No significant difference in genotype frequencies were found between cases and 
controls (p=0.260), MA and controls (p=0.563), nor MO and controls (p=0.133). There was also no 
significant difference in allele frequencies between cases and controls (p=0.333), MA and controls 
(p=0.370), nor MO and controls (p=0.593). The genotype and allele frequencies were also compared 
between migraineurs and controls sub-grouped into each of the genders (Table 1). No significant 
differences were seen between genotype or allele frequencies for female migraineurs compared to 
controls (p=0.270 and p=0.993, respectively). Similarly for the male sub-population, there was no 
significant difference between migraineurs and controls for either genotypes (p=0.163) or alleles 
(p=0.055), although the latter is close to significance. 
 
Table 1. Genotype and allele frequency distributions for the CALCA rs3781719 SNP in migraine and 
control groups and subgrouped by gender. 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
TT (%) TC (%) CC (%) T (%) C (%) 
          
Migraine 228 109 
(47.8) 
102 
(44.7) 
17 
(7.5) 
0.260 456 320 
(70.2) 
136 
(29.8) 
0.333 
MA 147 72 
(49.0) 
62 
(42.2) 
13 
(8.8) 
0.563 294 206 
(70.0) 
88 
(30.0) 
0.370 
MO 81 37 
(45.7) 
40 
(49.4) 
4 
(4.9) 
0.133 162  114 
(70.4) 
48 
(29.6) 
0.593 
Control 203 111 
(54.7) 
75 
(36.9) 
17 
(8.4) 
- 406 297 
(73.2) 
109 
(26.8) 
- 
 
          
Females          
Migraine 172 82 
(47.7) 
79 
(45.9) 
11  
(6.4) 
0.270 344 243 
(70.6) 
101 
(29.4) 
0.993 
Control 148 76 
(51.4) 
57 
(38.5) 
15 
(10.1) 
- 296 209 
(70.6) 
87 
(29.4) 
- 
          
Males          
Migraine 56 27 23 6  0.163 112 77 35 0.055 
(48.2) (41.1) (10.7) (68.8) (31.2) 
Control 55 35 
(63.6) 
18 
(32.7) 
2  
(3.6) 
- 110 88 
(80.0) 
22 
(20.0) 
- 
MA- Migraine with aura, MO- Migraine without aura 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
N is total number of genotypes or alleles. 
 
CALCA rs145837941 
A total of 462 individuals were genotyped for rs145837941, which included 236 migraine cases and 
226 controls (Table 2).  Because the CC genotype was very rare, the TC and CC genotypes were 
pooled together for analysis versus the wild type TT genotype for chi-square analysis between 
migraineurs and controls, however no significant difference was observed (p=0.913). Similarly there 
was no significant difference for alleles between cases and controls (p=0.926). No further analysis in 
subgroups was done because of the rarity of the C-allele. We found that rs3781719 and 
rs145837941 are not in linkage disequilibrium (LD) in our population (r2=0.06, p=0.389). 
Furthermore, neither marker is in LD with the 16 bp deletion polymorphism that we previously 
genotyped in this population (r2=0.088, p=0.205 for rs3781719 and r2=0.042, p=0.541 for 
rs145837941). The HapMap data release 27 shows poor variant coverage in this region. 
 
Table 2. Genotype and allele frequency distributions for the CALCA rs145837941 SNP in migraine 
and control groups 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
TT (%) TC (%) CC (%) T (%) C (%) 
          
Migraine 236 224 
(94.9) 
11  
(4.7) 
1  
(0.4) 
0.913 472 459 
(97.2) 
13  
(2.8) 
0.926 
Control 226 214 
(94.7) 
12  
(5.3) 
0  
(0) 
- 452 440 
(97.3) 
12  
(2.7) 
- 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
Because of the rarity of the C-allele, the P-value for genotypes was calculated for the TT genotype 
versus TC and CC genotypes pooled together. 
 
RAMP1 rs3754701 
A total of 485 individuals were successfully genotyped for rs3754701 comprised of 243 migraine 
cases (broken down into 145 MA and 98 MO patients), and 242 controls (Table 3). No significant 
difference was found for genotype frequencies between cases and controls (p=0.370), MA and 
controls (p=0.276), nor MO and controls (p=0.260) and for allelic frequencies between cases and 
controls (p=0.376), MA and controls (p=0.912), nor MO and controls (p=0.129). The genotype and 
allele frequencies were also compared between migraineurs and controls of the two genders (Table 
3). No significant differences were seen between genotypic or allelic frequencies for female 
migraineurs compared to controls (p=0.560 and p=0.819, respectively). For the male sub-population, 
although close, the difference between migraineurs and controls was not significant for genotypes 
(p=0.068), but a significant difference in the allelic frequency was observed between migraineurs 
and controls (p=0.031). However, to take into account the implications of multiple testing 
considering the entire group and sub-group analyses, Bonferroni correction the p-value to an alpha 
of 0.0056 renders the result non-significant. 
 Table 3. Genotype and allele frequency distributions for the RAMP1 rs3754701 SNP in migraine 
and control groups and subgrouped by gender. 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
TT (%) TA (%) AA (%) T (%) A (%) 
          
Migraine 243 91 
(37.4) 
120 
(49.4) 
32 
(13.2) 
0.360 494 302 
(61.1) 
184 
(38.9) 
0.376 
MA 145 61 
(42.1) 
65 
(44.8) 
19 
(13.1) 
0.276 290 187 
(64.5) 
103 
(35.5) 
0.912 
MO 98 30 
(30.6) 
55 
(56.1) 
13 
(13.3) 
0.260 196 115 
(58.7) 
81 
(41.3) 
0.129 
Control 242 94 
(38.8) 
126 
(52.1) 
22 
(9.1) 
- 484 314 
(64.9) 
170 
(35.1) 
 
          
Females          
Migraine 183 71 
(38.8) 
89 
(48.6) 
23 
(12.6) 
0.560 366 231 
(63.1) 
135 
(36.9) 
0.819 
Control 179 63 
(35.2) 
97 
(54.2) 
19 
(10.6) 
- 358 223 
(62.3) 
135 
(37.7) 
- 
          
Males          
Migraine 60 20 
(33.3) 
31 
(51.7) 
9 
(15.0) 
0.068 120 71 
(59.2) 
49 
(40.8) 
0.031 
Control 63 31 
(49.2) 
29 
(46.0) 
3 
(4.8) 
- 126 91 
(72.2) 
35 
(27.8) 
- 
MA- Migraine with aura, MO- Migraine without aura 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
N is total number of genotypes or alleles. 
 
RAMP1 rs7590387 
A total of 456 individuals were successfully genotyped for rs7590387, consisting of 226 migraine 
cases (138 MA and 88 MO patients), and 230 controls. A chi-square analysis (χ2) was performed to 
compare the allele and genotype frequencies of the migraine population to the controls (Table 4). 
No significant differences in genotypic frequencies were found between migraineurs and controls 
(p=0.341), MA and controls (p=0.566), nor MO and controls (p=0.299) and for allelic frequencies 
between migraineurs and controls (p=0.461), MA and controls (p=0.864), nor MO and controls 
(p=0.236). When migraineurs and controls were split into the two genders for analysis (Table 4), 
there were no significant differences between genotypic or allelic frequencies for female 
migraineurs compared to controls (p=0.865 and p=0.769, respectively), or for male migraineurs 
compared to controls (p=0.188 and p=0.366, respectively). According to CEPH Caucasian HapMap LD 
data rs3754701 and rs7590387 are not correlated (r2=0.005) and we also find in our population that 
these two SNPs are not in LD (r2=0.094, p=0.126). 
  
Table 4. Genotype and allele frequency distributions for the RAMP1 rs7590387 SNP in migraine 
and control groups and subgrouped by gender. 
Group N 
genotypes 
Genotypes P N 
alleles 
Alleles P 
GG (%) GC (%) CC (%) G (%) C (%) 
          
Migraine 226 58 
(25.7) 
123 
(54.4) 
45 
(19.9) 
0.341 452 239 
(52.1) 
213 
(47.1) 
0.461 
MA 138 33 
(23.9) 
75 
(54.3) 
30 
(21.7) 
0.566 276 141 
(51.1) 
135 
(48.9) 
0.864 
MO 88 25 
(28.4) 
48 
(54.5) 
15 
(17.0) 
0.299 176 98 
(55.7) 
78 
(44.3) 
0.236 
Control 230 60 
(26.1) 
112 
(48.7) 
58 
(25.2) 
- 460 232 
(50.4) 
228 
(49.6) 
- 
          
Females          
Migraine 171 44 
(25.7) 
93 
(54.4) 
34 
(19.9) 
0.865 342 181 
(52.9) 
161 
(47.1) 
0.769 
Control 172 43 
(25.7) 
87 
(52.1) 
37 
(22.2) 
- 334 173 
(51.8) 
161 
(48.2) 
- 
          
Males          
Migraine 55 14 
(25.5) 
30 
(54.5) 
11 
(20.0) 
0.188 110 58 
(52.7) 
52 
(47.3) 
0.366 
Control 63 17 
(27.0) 
25 
(39.7) 
21 
(33.3) 
- 126 59 
(46.8) 
67 
(53.2) 
- 
MA- Migraine with aura, MO- Migraine without aura 
P-values were calculated by χ2-analysis, significance was taken at P≤0.05. 
N is total number of genotypes or alleles. 
 
 
4. Discussion 
The identification of susceptibility genes for complex traits such as migraine can be challenging, in 
particular due to the contribution of multiple, and potentially interacting, loci as well as the 
confounding influence of environmental factors. However, unravelling the genetic basis of migraine 
should improve our understanding of the pathogenesis of the disease and may suggest pathways to 
which therapies can be targeted. Both the CALCA and RAMP1 genes are good candidates to 
investigate whether polymorphisms at these loci play a role in migraine pathogenesis and/or 
susceptibility due to the well-documented relationship of CGRP with migraine. However, neither the 
16-bp deletion in intron 1 of the CALCA gene that we tested previously (Menon et al., 2011), nor the 
two CALCA and two RAMP1 SNPs that we tested in this study, show a significant difference between 
the migraine and control groups, the MA and control groups, or the MO and control groups in this 
Australian population. In line with this, no positive association of the four SNPs in this study was 
found when the analysis was performed with female samples. An increase in frequency of the minor 
C-allele of the rs3781719 SNP in the promoter of the CALCA gene in male migraineurs was close to 
significance (p=0.055) and for one of the SNPs, rs3754701 which is in the promoter of the RAMP1 
gene, we observed a nominally significant increase in the frequency of the minor A-allele in male 
migraineurs (p= 0.031). However, the result is not significant with Bonferroni correction for multiple 
testing which gives a corrected p-value threshold of 0.0056. Because fewer males are affected by 
migraine than females, the number of male subjects in our population is low, so the association may 
be a false positive. However, sex-specific differences in mRNA levels of CGRP and CGRP receptor 
components including RAMP1 have been found before and after induction of migraine-like 
symptoms in a rat preclinical migraine model (Stucky et al., 2011); furthermore, sex- specific 
differences are also apparent in the migraine-relevant behaviour of light aversion in mice 
overexpressing transgenic RAMP1 (Recober et al., 2009), suggesting that the result is potentially 
interesting. Future studies could look at these markers using a larger cohort, in particular of male 
subjects, in order to follow up any potential associations. While female sex hormones have a role in 
migraine and may help explain the preponderance of female migraine sufferers (Shyti et al., 2011), 
polymorphisms in some genes have been more strongly linked in males to either migraine, such as 
DBH (Fernandez et al., 2006) or particular migraine phenotypes, such as the C667T polymorphism in 
MTHFR (Liu et al., 2010). 
The products of the CALCA gene including calcitonin, -CGRP, their propeptides and other cleavage 
products exert many functions in the body. Mutations in a calcitonin receptor have been associated 
with altered bone density and decreased fracture risk in postmenopausal women (Masi et al., 1998; 
Taboulet et al., 1998). CGRP is vasodilator in peripheral organs as well as the brain and 
polymorphisms in CALCA gene have been linked to essential hypertension in Japanese and Chinese 
populations (Morita et al., 2007; Luo et al., 2008). A previous study had found no difference between 
migraine cases and controls for another CALCA gene promoter SNP (rs1553005) in a European 
population (Lemos et al., 2010). According to CEPH Caucasian HapMap LD data rs1553005 is in 
complete LD with rs3781719, however, we decided to test rs3781719 in our migraine population for 
a number of reasons. Firstly, we have a greater proportion of MA compared to MO cases, which 
would give us greater power to detect any association that is specific for this subgroup of migraine, 
and furthermore, our population is primarily made up of Northern European, i.e. British 
descendants, compared to the Southern European Portuguese cohort of that study and there is 
some genetic disparity between European populations. However, we found no significant 
association of either of the CALCA SNPs in this study with overall migraine or either MA or MO. The 
Lemos et al. (2010) study also investigated SNPs at the BDNF locus and, while no individual 
associations were detected, an increased risk for one of the genotype pairs of their CALCA SNP 
rs1553005 and a BDNF SNP in migraineurs was found, suggesting interaction between these genes in 
migraine susceptibility. BDNF is co-expressed with CGRP in trigeminal ganglion neurons in rats and 
CGRP enhances the release of BDNF (Buldyrev et al., 2006) so future studies of CGRP-related genes 
in migraine could focus on interactions between loci. 
Many of the anti-migraine drugs currently available target some action of CGRP action. Triptans act 
in part by inhibiting trigeminal release of CGRP (Bigal et al., 2009), while olcegepant (BIBN-4096BS) 
and telcagepant (MK-0974) are CGRP receptor antagonists (Olesen et al., 2004; Ho et al., 2008; 
Edvinsson and Ho, 2010). Some migraineurs respond better with certain migraine drugs than others 
and some fail to respond at all; studies have investigated SNPs in some factors and genes that may 
be involved (Ishii et al., 2012). Although we failed to detect association with migraine for the CALCA 
and RAMP1 variations that we have looked at in this study, these genes could also potentially play a 
role in drug response to anti-migraine agents. 
In conclusion, we investigated whether the SNPs rs3754701 and rs7590387 in RAMP1 and rs3781719 
and rs145837941 in the CALCA locus are associated with migraine susceptibility. We find no 
significant association of any of the SNPs tested with migraine overall. We did detect a nominally 
significant association of the minor A-allele for RAMP1 rs3754701 in male migraine subjects, but this 
was no longer significant after Bonferroni correction. Although RAMP1, via its interaction with CGRP, 
has been implicated in migraine (Recober et al., 2009), our study is the first to investigate 
polymorphisms in the RAMP1 gene in a migraine population. Future studies using a larger 
population to increase the power to detect significant associations, and greater gene coverage and 
haplotype analysis, would clarify whether polymorphisms in CGRP-related genes play a role in 
migraine. 
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